$27.87−1.17 (−4.03%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Adaptive Biotechnologies (ADPT) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~15.7%/yr (FY21→FY25), net margin −21.5%. Worth your attention in FY25: Share count (+8.1%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲54.8%
277.0
FY21→FY25CAGR +15.7%/yr
Net income ($M)▲62.7%
−59.5
FY21→FY25CAGR —
Free cash flow ($M)▲50.5%
−48.9
FY21→FY25CAGR —
Diluted EPS▲63.9%
−0.39
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+8.1%
140.4mn → 151.7mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$3.0M
−19.2% YoY in FY25 · 1.1% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-21¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 68.1% → 74.2%. Net margin -21.5% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 298,010.0 | 276,976.0 | 178,957.0 | 170,276.0 | 185,308.0 | 154,344.0 | ▲54.8% | +15.7% |
Cost of revenue | 77,030.0 | 71,359.0 | 72,080.0 | 75,553.0 | 57,909.0 | 49,301.0 | ▼1.0% | +9.7% |
Gross profit | 220,980.0 | 205,617.0 | 106,877.0 | 94,723.0 | 127,399.0 | 105,043.0 | ▲92.4% | +18.3% |
Research & development | 83,177.0 | 93,769.0 | 102,953.0 | 122,117.0 | 141,756.0 | 142,343.0 | ▼8.9% | −9.9% |
Selling, general & admin | 80,173.0 | 72,701.0 | 72,806.0 | 83,934.0 | 88,527.0 | 74,502.0 | ▼0.1% | −0.6% |
Total operating expenses | 269,186.0 | 262,740.0 | 269,426.0 | 321,758.0 | 327,585.0 | 314,009.0 | ▼2.5% | −4.4% |
Operating incomefeeds ROC rank | −48,206.0 | −57,123.0 | −162,549.0 | −227,035.0 | −200,186.0 | −208,966.0 | ▲64.9% | — |
Other income, net | −22,523.0 | −2,334.0 | 2,954.0 | 1,731.0 | −182.0 | 1,668.0 | — | — |
Pretax income | −70,729.0 | −59,457.0 | −159,595.0 | −225,304.0 | −200,368.0 | −207,298.0 | ▲62.7% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −70,729.0 | −59,457.0 | −159,595.0 | −225,304.0 | −200,368.0 | −207,298.0 | ▲62.7% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −0.44 | −0.39 | −1.08 | −1.56 | −1.40 | −1.48 | ▲63.9% | — |
Diluted shares (mn) | 186.88 | 151.72 | 147.10 | 144.38 | 142.52 | 140.35 | ▲3.1% | +2.0% |
| Margins | ||||||||
Gross margin66th pct in Healthcare | 74.2% | 74.2% | 59.7% | 55.6% | 68.7% | 68.1% | ▲14.5pp | +6.2pp |
Operating margin | −16.2% | −20.6% | −90.8% | −133.3% | −108.0% | −135.4% | ▲70.2pp | +114.8pp |
Net margin21st pct in Healthcare | −23.7% | −21.5% | −89.2% | −132.3% | −108.1% | −134.3% | ▲67.7pp | +112.8pp |
† TTM = trailing four quarters through 2026-09-30.
4 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Adaptive Biotechnologies' revenue last fiscal year?
Adaptive Biotechnologies reported revenue of $277.0M in fiscal 2025, up 54.8% from fiscal 2024.
What was Adaptive Biotechnologies' net income?
Adaptive Biotechnologies reported net income of −$59.5M in fiscal 2025, a net margin of −21.5%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

